These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 31658379)

  • 1. Population pharmacokinetics of a triple-secured fibrinogen concentrate administered to afibrinogenaemic patients: Observed age- and body weight-related differences and consequences for dose adjustment in children.
    Bellon A; Fuseau E; Roumanie O; Lamazure J; Stevens W; Dahmane A; Barthez-Toullec M; Golly D; Henriet C; Bridey F
    Br J Clin Pharmacol; 2020 Feb; 86(2):329-337. PubMed ID: 31658379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology, Efficacy and Safety of a Triple-Secured Fibrinogen Concentrate in Children Less than or Equal to 12 Years with Afibrinogenaemia.
    Djambas Khayat C; El Khorassani M; Aytaç S; Harroche A; Dahmane A; Pujol S; Henriet C; de Moerloose P; Bridey F
    Thromb Haemost; 2020 Jun; 120(6):957-967. PubMed ID: 32392604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of fibrinogen concentrate.
    Manco-Johnson MJ; Dimichele D; Castaman G; Fremann S; Knaub S; Kalina U; Peyvandi F; Piseddu G; Mannucci P;
    J Thromb Haemost; 2009 Dec; 7(12):2064-9. PubMed ID: 19804533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, efficacy and safety of a novel fibrinogen concentrate in pediatric patients with congenital afibrinogenemia.
    Khayat CD; Navarro-Puerto J; Ross CR; Subramanian K; Kalappanavar NK; Rucker K; Liang W; Mondou E
    Blood Coagul Fibrinolysis; 2023 Jan; 34(1):61-69. PubMed ID: 36484281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology, efficacy and safety study of a triple-secured fibrinogen concentrate in adults and adolescent patients with congenital fibrinogen deficiency.
    Djambas Khayat C; El Khorassani M; Lambert T; Gay V; Barthez-Toullec M; Lamazure J; Bellon A; Henriet C; Bridey F; Négrier C
    J Thromb Haemost; 2019 Apr; 17(4):635-644. PubMed ID: 30661302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of fibrinogen concentrate pharmacokinetics and dosing for bleeds and surgery in adults, adolescents, and children with congenital afibrinogenaemia and hypofibrinogenaemia.
    Djambas Khayat C; Lohade SD; Zekavat OR; Kruzhkova I; Solomon C; Knaub S; Peyvandi F
    Haemophilia; 2022 Nov; 28(6):1022-1032. PubMed ID: 35925493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic modelling of fibrinogen in patients with congenital or acquired-chronic or acute-hypofibrinogenaemia.
    Colom H; Blasi A; Montoro B; Arévalo AG; Cendrós JM; Sabaté A
    Br J Clin Pharmacol; 2023 Sep; 89(9):2703-2713. PubMed ID: 37041125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fibrinogen concentrate for on-demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency.
    Djambas Khayat C; Lohade S; D'Souza F; Shamanur LG; Zekavat OR; Kruzhkova I; Schwartz B; Solomon C; Knaub S; Peyvandi F
    Haemophilia; 2021 Mar; 27(2):283-292. PubMed ID: 33326665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.
    Ross C; Rangarajan S; Karimi M; Toogeh G; Apte S; Lissitchkov T; Acharya S; Manco-Johnson MJ; Srivastava A; Brand B; Schwartz BA; Knaub S; Peyvandi F
    J Thromb Haemost; 2018 Feb; 16(2):253-261. PubMed ID: 29220876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate.
    Négrier C; Rothschild C; Goudemand J; Borg JY; Claeyssens S; Alessi MC; Jaffry AC; Teboul C; Padrazzi B; Waegemans T
    J Thromb Haemost; 2008 Sep; 6(9):1494-9. PubMed ID: 18627444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia.
    Ross CR; Subramanian S; Navarro-Puerto J; Subramanian K; Kalappanavar NK; Khayat CD; Acharya SS; Peyvandi F; Rucker K; Liang W; Vilardell D; Trimm S; Ayguasanosa J
    Thromb Res; 2021 Mar; 199():110-118. PubMed ID: 33486319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency.
    Peyvandi F
    Thromb Res; 2009 Dec; 124 Suppl 2():S9-11. PubMed ID: 20109654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism.
    Röshammar D; Huang F; Albisetti M; Bomgaars L; Chalmers E; Luciani M; Halton J; Mitchell LG; Bergstrand M; Ibrahim MMA; Joseph D; Tartakovsky I; Gropper S; Brueckmann M; Brandão LR
    J Thromb Haemost; 2021 May; 19(5):1259-1270. PubMed ID: 33636042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
    van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
    Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register.
    Weiss G; Lison S; Glaser M; Herberger S; Johanning K; Strasser T; Huber T; Spannagl M; Heindl B
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):727-34. PubMed ID: 22024795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
    Guidi M; Mercier T; Aouri M; Decosterd LA; Csajka C; Ogutu B; Carn G; Kiechel JR
    Malar J; 2019 Apr; 18(1):139. PubMed ID: 30999915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three successful deliveries involving a woman with congenital afibrinogenaemia - conventional fibrinogen concentrate infusion vs. 'as required' fibrinogen concentrate infusion based on changes in fibrinogen clearance.
    Oda T; Itoh H; Kawai K; Oda-Kishimoto A; Kobayashi T; Doi T; Uchida T; Kanayama N
    Haemophilia; 2016 Sep; 22(5):e478-81. PubMed ID: 27481286
    [No Abstract]   [Full Text] [Related]  

  • 18. Population Pharmacokinetics of Intraperitoneal Bupivacaine Using Manual Bolus Atomization Versus Micropump Nebulization and Morphine Requirements in Young Children.
    Meier PM; Pereira LM; Zurakowski D; Nguyen HT; Munoz-San Julian C; Houck CS
    Anesth Analg; 2019 Oct; 129(4):963-972. PubMed ID: 31124839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinogen Concentrate as an Alternative to Cryoprecipitate in a Postcardiopulmonary Transfusion Algorithm in Infants Undergoing Cardiac Surgery: A Prospective Randomized Controlled Trial.
    Downey LA; Andrews J; Hedlin H; Kamra K; McKenzie ED; Hanley FL; Williams GD; Guzzetta NA
    Anesth Analg; 2020 Mar; 130(3):740-751. PubMed ID: 31490252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP.
    Baudry E; Huguet S; Couderc AL; Chaibi P; Bret F; Verny C; Weill S; Madar O; Urien S; Rezai K
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):775-785. PubMed ID: 30689002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.